Heart Failure Management Program Versus Usual Care
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01822912|
Recruitment Status : Completed
First Posted : April 4, 2013
Last Update Posted : August 7, 2019
Heart Failure (HF) patients discharged to Skilled Nursing Facilities have higher rehospitalization rates and mortality than patients discharged to home.
HF disease management programs have been shown to reduce rehospitalizations in community settings, no national guidelines have been set forth for Skilled Nursing Facilities (SNF).
This study will investigate the the effect of a heart failure-disease management program on the outcome of all-cause hospital readmissions, emergency room admissions and mortality for 30 days post-SNF admission using 7 component heart failure disease management program.
|Condition or disease||Intervention/treatment||Phase|
|Cardiac Failure Congestive Heart Failure||Other: Heart Failure Disease Management Program Other: Heart Failure Usual Care||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||713 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of a Skilled Nursing Facility Heart Failure Disease Management Program Versus Usual Care|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||May 2018|
|Actual Study Completion Date :||March 2019|
Active Comparator: Heart Failure Disease Management Program
Patients will receive personalized care to include medication titration, daily weights, symptom and activity assessment, documentation of ejection fraction, patient and caregiver education,dietary surveillance, discharge instructions and follow up visit within 7 days of SNF discharge
Other: Heart Failure Disease Management Program
Subjects will be assessed 3 times a week while in SNF.
Placebo Comparator: Heart Failure Usual Care
SNF patients with HF will receive usual care
Other: Heart Failure Usual Care
Subjects will receive standard of care.
- Change in 60 day post SNF admission outcomes [ Time Frame: Up to 60 days post SNF admission ]To determine the difference in the composite endpoint of 60-day all-cause hospitalization, all-cause emergency department visits and all-cause mortality between HF patients in Skilled Nursing Facilities cared for by a heart failure-disease management program vs usual care.
- Difference in health status and self-care 60 days post SNF admission [ Time Frame: 60 days post SNF admission ]To compare the difference in health status and self-care for patients with HF cared for by a SNF heart failure-disease management program vs usual care 60 days post SNF admission. Health Status will be measured by the KCCQ (Kansas City Cardiomyopathy Questionnaire) which is a 23 item questionnaire specific for patients with HF. It includes aspects of physical function, symptoms (frequency, severity and stability), social function, self-efficacy, knowledge, and quality of life. HF Self Management will be measured using the SCHFI (Self-Care HF Index) which consists of 15 item scale with 3 domains of self care including self care maintenance (behaviors to maintain clinical stability), self-care management (decision making process with regard to symptom changes), and confidence to manage symptoms.
- Change in Patients living at home 60 days post-SNF admission with Heart Failure (HF) [ Time Frame: 60 days post SNF admission ]To determine if a SNF HF disease management program vs. usual care results in a greater proportion of HF patients who were previously living at home return home vs. admission to long term care post SNF discharge.
- Difference in Cost-effectiveness [ Time Frame: Up to 60 days post SNF admission ]To assess the cost-effectiveness of heart failure disease management program vs usual care for SNF patients with HF
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01822912
|United States, Colorado|
|University of Colorado|
|Aurora, Colorado, United States, 80045|
|Principal Investigator:||Rebecca Boxer, MD||University of Colorado, Denver|